Skin-Homing Interleukin-4 and -13-Producing Cells Contribute to Bullous Pemphigoid: Remission of Disease is Associated with Increased Frequency of Interleukin-10-Producing Cells  by Teraki, Yuichi et al.
Skin-Homing Interleukin-4 and -13-Producing Cells
Contribute to Bullous Pemphigoid: Remission of Disease is
Associated with Increased Frequency of Interleukin-10-
Producing Cells
Yuichi Teraki, Takayuki Hotta, and Tetsuo Shiohara
Department of Dermatology, Kyorin University School of Medicine, Mitaka, Tokyo, Japan
Although evidence is accumulating that type 2 cyto-
kines play a part in the pathogenesis of bullous pem-
phigoid, little information is available concerning
characterization of the cellular source of these cyto-
kines involved in the pathogenesis of bullous pem-
phigoid. By using multiparameter ¯ow cytometry,
we investigated T cells capable of producing inter-
leukin-2, -4, -10, and -13, interferon-g, and tumor
necrosis factor-a and their correlated expression of
skin-homing receptor (cutaneous lymphocyte-associ-
ated antigen) in peripheral blood and skin blister of
patients with bullous pemphigoid. In peripheral
blood of bullous pemphigoid patients, signi®cantly
increased frequencies of interleukin-4- and inter-
leukin-13-producing cells were found as compared
with those of healthy controls, and the majority of
these type 2 cells was found in the cutaneous lym-
phocyte-associated antigen-positive population. The
frequency of interferon-g-producing cells was also
increased as compared with healthy subjects; how-
ever, the majority of this subset was found in the
cutaneous lymphocyte-associated antigen-negative
population. In the skin blister, the frequencies of
interleukin-13- and interleukin-4-producing cells
were much higher than those in the peripheral blood
of bullous pemphigoid, whereas that of interferon-g
producing cells was signi®cantly lower. Furthermore,
in bullous pemphigoid patients after therapy with
systemic corticosteroids, the frequency of cutaneous
lymphocyte-associated antigen-positive, but not
cutaneous lymphocyte-associated antigen-negative,
interleukin-13-producing cells was signi®cantly
decreased accompanied by an increased frequency of
interleukin-10-producing cells, which was associated
with clinical improvement. Thus, our results suggest
that bullous pemphigoid is a unique organ-speci®c
autoimmune disease characterized by an expansion
of skin-homing interleukin-13-producing cells. In
addition, corticosteroids may control such type 2
biased in¯ammatory responses in bullous pemphi-
goid by promoting the expansion of interleukin-10-
producing cells. Key words: bullous pemphigoid/
cutaneous lymphocyte-associated antigen/cytokine/T lym-
phocyte. J Invest Dermatol 117:1097±1102, 2001
B
ullous pemphigoid (BP) is the most common auto-
immune blistering skin disease characterized by the
presence of autoantibodies against hemidesmosomal
protein of basement membrane zone (Nousari and
Anhalt, 1999). Although two antigens (BP230 and
BP180) are recognized by autoantibodies, several lines of evidence
have demonstrated that only autoantibodies against the BP180
antigen are pathogenic and induce blistering (Liu et al, 1993).
Nevertheless, mediators other than autoantibodies may be also
involved in the ongoing cutaneous in¯ammation of BP. Recent
studies have shown that a variety of cytokines levels are elevated in
the blister ¯uid of BP (Schmidt et al, 1996; Ameglio et al, 1998;
D'Auria et al, 1998), suggesting that cytokines may play a part in
the in¯ammatory responses of BP; however, the exact cellular
source of these cytokines has not yet been identi®ed. In this respect,
it is important to clarify the cytokine pro®le of T cells involved in
BP, because T lymphocytes are a major source of cytokines; BP is
accompanied by varying degrees of skin in¯ammation characterized
histologically by perivascular and subepidermal in®ltrates of T cells
(Nestor et al, 1987); and T cells are involved in the initiation and
perpetuation of a variety of autoimmune diseases (Romagnani,
1994; Libleau et al, 1995).
According to current understanding, organ-speci®c homing
receptor directs lymphocytes into the target organ (Butcher and
Picker, 1996). In humans, skin-homing memory T cell subset is
characterized by the preferential expression of cutaneous lympho-
cyte-associated antigen (CLA) (Picker et al, 1990). It has been
demonstrated that T cells expressing CLA accumulate selectively
into the skin (Picker et al, 1993, 1994) and that antigen-speci®c T
cells responsible for skin-associated immune reactions are prefer-
entially found in the CLA+ fraction of memory cells (Rossiter et al,
1994; Santamaria et al, 1995). In this regard, we predicted that the
skin-homing T cells might determine the cellular immunity of BP
because BP is a unique skin-speci®c autoimmune disease.
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In this study, we investigated the cytokine synthesis capabilities
of T cells and their correlated expression of CLA in the peripheral
blood (PB) and skin blister of BP patients at the single cell level
using ¯ow cytometry. Here we demonstrate a signi®cantly higher
frequency of skin-homing interleukin (IL)-4- and IL-13-producing
cells with selective expression of CLA in the PB of BP patients.
Indeed, preferential accumulation of IL-4- and IL-13-producing
cells was found in the skin blister. Furthermore, in BP patients after
therapy with corticosteroids, the frequency of CLA+, but not
CLA±, IL-13-producing cells were signi®cantly decreased accom-
panied by an increased frequency of IL-10-producing cells, which
was associated with a parallel improvement in their clinical
condition.
MATERIALS AND METHODS
BP patients Blood samples and blister ¯uid were obtained from eight
patients with BP (four males, four females). All patients ful®lled the
clinical, histologic, and immuno¯uorescent criteria of BP. We excluded
patients who had other types of systemic illnesses such as infectious
disease, allergic disease, and cancer, which could affect the outcome of
study. After a diagnosis of BP, all patients were treated with prednisolone
(initial daily dose: about 1 mg per kg). Steroid therapy improved the
bullous lesions within 3±4 wk in all patients. The serum IgE level ranged
from 241 to 11,827 IU per ml (average: 3587). Eleven healthy subjects
and seven patients with allergic asthma (the average of serum IgE level:
2707 IU per ml) without systemic steroid therapy served as controls.
Monoclonal antibodies The CLA-speci®c ¯uorescein isothiocyanate
(FITC)-conjugated rat monoclonal antibody HECA-452 was kindly
provided by Dr Louis J. Picker (UT South-western Medical Center,
Dallas, TX). Monoclonal antibodies anti-CD3 [phycoerythrin (PE),
allophycocyanin (APC)], anti-CD4 (PE, peridinin chlorophyll protein
(PerCP), APC), anti-CD8 (PE, PerCP), anti-IL-2 (FITC, PE), anti-IL-4
(PE), anti-IL-10 (PE), and anti-IL-13 (PE), anti-interferon (IFN)-g
(FITC, PE), anti-tumor necrosis factor (TNF)-a (FITC, PE), and isotype
controls were obtained from Becton Dickinson (San Jose, CA).
Cell preparation Peripheral blood mononuclear cells were isolated
from heparinized venous blood or blister ¯uid of BP patients by density-
gradient sedimentation over Ficoll-Hypaque (Histopaque; Sigma, St
Louis, MO). Cells were stored at ±80°C until the analysis of cytokine
synthesis capability.
Flow-cytometric assays Simultaneous ¯ow-cytometric assessment of
T cell phenotype and cytokine synthesis was performed as previously
described (Teraki and Picker, 1997). Brie¯y, frozen cells were quickly
thawed at 37°C, and were washed with Hank's. Then, cells were
stimulated for 4 h in complete RPMI 1640 medium (supplemented with
10% fetal bovine serum, 10 mM HEPES buffer, 0.5 mM 2-mercapto-
ethanol (2-ME), 2 mM glutamine, 1 mM sodium pyruvate, 100 U
penicillin per ml, and 100 mg streptomycin per ml) containing 25 ng
phorbol 12-myristate 13-acetate per ml (Sigma), 1 mM ionomycin
(Sigma), and 10 mg Brefeldin A per ml (Sigma). After harvesting, cells
were directly stained with cell surface marker for 25 min at 4°C. After
washing with phosphate-buffered saline containing 0.1% bovine serum
albumin, cells were incubated in 0.5 ml of lysing solution and 0.5 ml of
permeabilizing solution (Becton Dickinson) at room temperature, washed
with phosphate-buffered saline/bovine serum albumin, and then
incubated for 25 min with monoclonal antibody speci®c to
¯uorochrome-conjugated IL-2, IL-4, IL-10, IL-13, IFN-g, and TNF-a.
After staining, the cells were washed and resuspended in 0.5 ml of 1%
paraformaldehyde in phosphate-buffered saline before ¯ow cytometric
analysis. The samples were analyzed with four color staining using
FACSCalibur Flow Cytometer (Becton Dickinson). List mode
multiparameter data ®les were analyzed using the PAINT-A-GATEplus
program (Becton Dickinson). The percentage of cytokine staining was
determined by subtracting control staining from test staining.
Statistical analysis The results are expressed as the mean 6 SEM.
Statistical analyses were made by Mann±Whitney's U test, paired t test.
p < 0.05 was considered signi®cant.
RESULTS
Flow cytometric quantitation of CLA-expressing CD4+ and
CD8+ T cells in the PB and skin blister ¯uid of BP
patients The CD4+ and CD8+ T cell subsets in PB and blister
¯uid of BP patients were identi®ed by ¯ow cytometry. The ratio of
CD4+ to CD8+ T cells in PB and skin blister was 2.45 6 0.36 and
3.40 6 0.42, respectively. As shown in Table I, CLA expression
by CD4+ and CD8+ T cells in PB was 14.7 6 1.9% and
9.3 6 1.7%, respectively. No signi®cant difference in CLA
expression by PB T cells was observed between BP patients and
healthy subjects (CD4: 13.8 6 1.1%, CD8: 5.4 6 0.9%). CLA
expression by CD8+ T cells (3.4 6 0.4%, p = 0.0012), but not
Table I. CLA expression by T cells in PB and skin blister
of BP patientsa
PBMC Skin blister ¯uid
CD4 CD8 CD4 CD8
14.7 6 1.9 9.3 6 1.7 82.7 6 2.7 62.3 6 1.9
aResults are expressed as mean 6 SEM.
Figure 1. A comparison of the percentages
of cytokine-producing cells among CD4+
and CD8+ T cells of PB between BP patients
and controls (healthy subjects and asthmatic
patients). Puri®ed PB T cells were stimulated
with phorbol 12-myristate 13-acetate +
ionomycin for 4 h in the presence of Brefeldin A,
and then were examined for cytokine synthesis
capabilities at the single cell level (CD3+ CD8±-
gated and CD3+ CD8+-gated T cells) using ¯ow
cytometry (CD4 expression is lost with phorbol
12-myristate 13-acetate stimulation and cannot be
used for gating in their experiments; in each
group, the vast majority of CD8± T cells are
CD4+). Results are expressed as mean 6 SEM.
Statistical signi®cance in differences between BP
patients and controls is indicated by *p < 0.05 and
**p < 0.01 (Mann±Whitney U test).
1098 TERAKI ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
CD4+ T cells (11.2 6 0.9%), in asthmatic patients was signi®cantly
lower than that in BP patients. On the other hand, CLA expression
by CD4+ and CD8+ T cells in the skin blister was 82.7 6 2.7% and
62.3 6 1.9%, respectively. These results show that CLA+ T cells
preferentially accumulate in the skin blister of BP.
Not only the frequencies of IL-4- and IL-13- but also IFN-g-
producing cells are signi®cantly increased in the PB of BP
patients Cytokine synthesis capabilities of PB T cells in BP
patients were evaluated at the single cell level using intracellular
cytokine staining after stimulation with phorbol 12-myristate 13-
acetate and ionomycin. Figure 1 shows cytokine synthesis
capabilities of CD4+- and CD8+-gated PB T cells in BP patients
and controls. In both CD4+ and CD8+ T cells, the frequencies of
IL-4-, IL-13-, and IFN-g-producing cells were signi®cantly higher
in BP patients than healthy subjects (CD4, IL-4: 4.2 6 0.8 vs
1.7 6 0.2%, p = 0.0082; IL-13: 3.9 6 0.7 vs 1.2 6 0.3%, p
= 0.0039; IFN-g: 35.8 6 6.3 vs 18.1 6 2.0%, p = 0.0105; CD8,
IL-4: 3.4 6 1.1 vs 0.7 6 0.1%, p = 0.0050; IL-13: 3.5 6 1.0 vs
0.5 6 0.1%, p = 0.0011; IFN-g: 55.2 6 5.2 vs 39.5 6 4.7%,
p = 0.0318). In CD8+ T cells, the frequency of TNF-a-producing
cells was signi®cantly higher in BP patients than healthy subjects
(70.0 6 3.1 vs 40.5 6 6.6%, p = 0.0098). No signi®cant
differences in the frequency of IL-2- or IL-10-producing cells
were observed between BP patients and healthy subjects. We also
compared the cytokine synthesis capabilities of PB T cells in BP and
asthmatic patients. In both CD4+ and CD8+ T cells, the frequency
of IL-10-producing cells was signi®cantly higher in asthmatic
patients than BP patients (CD4, 3.9 6 0.7 vs 0.6 6 0.1%, p
= 0.0019; CD8, 3.2 6 0.5 vs 0.6 6 0.1%, p = 0.0019). In CD8+ T
cells, but not CD4+ T cells, the frequencies of IL-4- and IL-13-
producing cells were signi®cantly higher in BP patients than
asthmatic patients (IL-4: 3.4 6 1.1 vs 0.8 6 0.2%, p = 0.0279; IL-
13: 3.5 6 1.0 vs 1.1 6 0.2, p = 0.0279). No signi®cant differences
in the frequency of IFN-g-, IL-2-, or TNF-a- producing cells
were observed between BP and asthmatic patients. These results
indicate that not only frequencies of type 2- (IL-4 and IL-13) but
also type 1-(IFN-g) cytokine-producing cells expand in the PB of
BP patients. Even if the frequencies of CD8+ IL-4 and IL-13-
producing cells in BP patients were compared with those in
Figure 2. A comparison of the percentages
of cytokine-producing cells among CD4+
and CD8+ T cells between PB vs skin blister
in BP patients. Results are expressed as
mean 6 SEM. Statistical signi®cance in data is
indicated by *p < 0.05 and **p < 0.01 (Mann±
Whitney U test).
Figure 3. A comparison of the percentages
of cytokine-producing cells among CLA+ vs
CLA± subsets in PB T cells of BP patients.
The data are shown as the percentages of
cytokine-producing cells on CLA+ vs CLA± gated
CD4+ and CD8+ T cells in PB. Results are
expressed as mean 6 SEM. Statistical signi®cance
in data is indicated by *p < 0.05 and **p < 0.01
(Mann±Whitney U test).
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asthmatic patients, they were high. On the other hand, the
frequency of IL-10-producing cells was not increased in the PB of
BP patients before the steroid therapy.
IL-4-, IL-10-, and IL-13-producing cells preferentially
accumulate in the skin blister of BP patients We next
examined the cytokine synthesis capabilities of T cells in the skin
blister of BP patients and compared them with those in the PB of
BP patients. As shown in Fig 2, in both CD4+ and CD8+ T cells,
the frequencies of IL-4-, IL-10-, and IL-13-producing cells were
signi®cantly higher in skin blister than the PB (CD4, IL-4:
9.2 6 0.9 vs 4.2 6 0.8%, p = 0.0016; IL-10: 2.1 6 0.4 vs
0.8 6 0.1%, p = 0.0016; IL-13: 17.8 6 2.7 vs 3.9 6 0.7%, p
= 0.0008; CD8, IL-4: 11.0 6 2.3 vs 3.4 6 1.1%, p = 0.0117; IL-
10: 1.4 6 0.3 vs 0.6 6 0.1%, p = 0.0157; IL-13: 12.8 6 2.7 vs
3.5 6 1.0%, p = 0.0087). By contrast, the frequencies of IFN-g-
producing cells (in both CD4+ and CD8+ T cells) and TNF-a-
producing cells (in CD4+ T cells) were signi®cantly lower in the
skin blister than in the PB (CD4, IFN-g: 11.3 6 2.6 vs
35.8 6 6.3%, p = 0.0063; TNF-a: 41.4 6 6.4 vs 67.0 6 3.1%,
p = 0.0087; CD8, IFN-g: 32.7 6 5.5 vs 55.2 6 5.2%, p = 0.0209).
No signi®cant difference in IL-2-producing cells was observed
between the skin blister and PB. These results indicate that type 2
cytokine-producing cells preferentially accumulate in the lesional
skin of BP.
Type 2 cytokine-producing cells selectively express CLA in
the PB of BP patients To con®rm if type 2 cytokine-producing
cells selectively express CLA, we examined the correlated
expression of CLA by cytokine-producing T cells in PB of BP
patients. Figure 3 showed the cytokine synthesis capabilities of
CLA+ vs CLA± subset. In both CD4+ and CD8+ T cells, the
frequencies of IL-2-, IL-4-, IL-10-, and IL-13-producing cells
were signi®cantly higher in the CLA+ than the CLA± subset (CD4,
IL-2: 42.5 6 2.4 vs 28.7 6 3.7%, p = 0.0460; IL-4: 9.1 6 2.2 vs
3.5 6 0.6%, p = 0.0357; IL-10: 1.1 6 0.2 vs 0.7 6 0.1%, p
= 0.0157; IL-13: 15.6 6 3.6 vs 1.3 6 0.1%, p = 0.0023; CD8, IL-
2: 33.4 6 6.8 vs 19.1 6 6.7%, p = 0.0063; IL-4: 7.0 6 1.4 vs
3.1 6 1.0%, p = 0.0181; IL-10: 1.5 6 0.3 vs 0.6 6 0.1%, p
= 0.0239; IL-13: 13.6 6 2.5 vs 2.8 6 0.9%, p = 0.0008). By
contrast, the frequency of IFN-g-producing cells was signi®cantly
lower among the CLA+ than the CLA± subset of CD4+ T cells
(24.5 6 4.1 vs 40.5 6 7.7%, p = 0.0460). No signi®cant difference
in TNF-a-producing cells was observed between the CLA+ and
CLA± subsets. These results indicate that the majority of type 2
subsets in the PB of BP patients express CLA.
A decrease in frequency of skin-homing IL-13-producing
cells is accompanied by an increase in frequency of IL-10-
producing cells after clinical improvement To determine
which cytokines are involved in the outcome of disease, we
measured cytokine-producing T cells in the PB of BP patients
before and after therapy with systemic corticosteroids (Fig 4). The
cytokine analyses after therapy were performed at 3±5 wk after
steroid therapy was started when skin lesions had been improved.
In both CLA+ and CLA± subsets, the frequency of IL-10-
producing cells was signi®cantly increased after clinical
improvement by corticosteroid therapy (CLA+ CD4: 1.1 6 0.2
vs 3.2 6 0.4%, p < 0.0001; CLA+ CD8: 1.5 6 0.3 vs 2.9 6 0.4%,
p = 0.0283; CLA± CD4: 0.7 6 0.1 vs 2.4 6 0.4%, p = 0.0013;
CLA± CD8: 0.6 6 0.1 vs 2.0 6 0.4%, p = 0.0137). The frequency
of IL-13-producing cells was signi®cantly decreased in CLA+
subset, but not in CLA± (CD4: 15.6 6 3.6 vs 5.5 6 0.8%,
p = 0.0118; CD8: 13.6 6 2.5 vs 8.1 6 1.6%, p = 0.0428).
Figure 4. A comparison of the percentages of cytokine-producing cells among CLA+ vs CLA± subsets in PB of BP patients before and
after corticosteroid therapy. Statistical signi®cance in data between before and after therapy is indicated by *p < 0.05 and **p < 0.01 (paired t test).
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No signi®cant difference was observed in other cytokine-
producing cells between before and after therapy. These results
suggest that among these T cells skin-homing IL-13-producing
cells play the most crucial part in the development of BP lesions,
whereas IL-10-producing cells are involved in the remission of BP.
DISCUSSION
Although several reports have suggested that type 2 helper cells may
be involved in the pathogenesis of BP (Schmidt et al, 1996; DePita
et al, 1997; Rico et al, 1999), no detailed analysis regarding the
cytokine patterns of T lymphocytes has been reported in BP. As
most of the previous data regarding cytokines in the serum and skin
blister of BP patients have been measured by enzyme-linked
immunosorbent assay or bioassay, the exact cellular source of these
cytokines has not yet been identi®ed. In this study, we demon-
strated the cytokine synthesis capabilities of T cells and their
correlated expression of CLA in PB and the skin blister of BP
patients at the single cell level using ¯ow cytometry. In PB of BP
patients, although no signi®cant difference in the CLA expression
by CD4+ and CD8+ T cells was observed between BP patients and
healthy subjects, signi®cantly increased frequencies of IL-4- and IL-
13-producing cells were observed as compared with healthy
subjects. Compared with asthmatic patients, signi®cantly increased
CLA expression and frequencies of IL-4- and IL-13-producing cells
in CD8+ T cells, but not CD4+ T cells, were signi®cantly increased
in BP patients. In the skin blister, the vast majority of CD4+ and
CD8+ T cells expressed CLA, and the frequencies of IL-4- and IL-
13-producing cells were much higher than those in PB of BP
patients, indicating that these type 2 cells seem to migrate into the
lesional skin based on CLA expression. Furthermore, in BP patients
after therapy with systemic corticosteroids, the frequency of CLA+,
but not CLA±, IL-13-producing cells was signi®cantly decreased in
association with clinical improvement. Taken together, these
results suggest that BP is a unique organ-speci®c autoimmune
disease characterized by a preferential expansion of skin-homing
type 2 cytokine-producing cells. Among these T cells, skin-homing
IL-13-producing cells may play the most crucial part in the local
immune responses of BP.
Most BP patients have elevated IgE (Asbrink and Hovmark,
1984) levels in sera and blister ¯uid, which positively correlate with
disease activity and titers of anti-basement membrane zone
antibodies (Hadi et al, 1988; Soh et al, 1993; Dopp et al, 2000).
In addition, IgG4 subclass and IgE class autoantibodies against
basement membrane zone are frequently found in the skin blister
and serum of BP patients (Delaporte et al, 1996; Dopp et al, 2000).
These ®ndings are consistent with our results because IL-4 and IL-
13 enhance the proliferation of preactivated B cells and direct
human B lymphocytes to switch to IgG4 and IgE synthesis (Borish
and Rosenwasser, 1996; Corry, 1999).
Generally, type 1 and type 2 cells antagonize each other (Abbas
et al, 1996; Borish and Rosenwasser, 1996). Therefore, it is of
interest that the frequencies of not only IL-4- and IL-13-producing
cells but also IFN-g-producing cells were signi®cantly increased in
the PB of BP patients, although the frequency of IFN-g-producing
cells was signi®cantly lower in the skin blister than the PB of BP.
One possibility is that the frequency of T cells capable of producing
both IL-4 (or IL-13) and IFN-g is increased in BP patients. In
support of this possibility, Budinger et al (1998) has recently shown
that autoreactive T cells responding to BPA2 in BP patients
produce both type 1 and type 2 cytokine. This possibility is
unlikely, however, because we were not able to detect a signi®cant
T cell population producing both type 1 and type 2 cytokines in
either PB or skin blister of BP patients (data not shown). Another
possibility is that IFN-g-producing cells may expand to protect the
skin from type 2-dominated immune responses in BP. This
possibility is also unlikely because the frequency of IFN-g-
producing cells remained unchanged before and after therapy.
Previous studies have shown that CD4+ T cells are the major
population of BP lesions (Nestor et al, 1987). Our study showed
that a substantial number of CD8+ T cells were recruited into the
lesional skin, although the ratio of CD4+ to CD8+ T cells was
somewhat lower in the skin blister than PB. In this context, it
should be noted that the vast majority of CD4+ T cells in the skin
blister was CLA positive, whereas nearly 40% of the corresponding
CD8+ T cells were negative for CLA. In addition, in the skin
blister, the frequency of type 2 cells was signi®cantly increased,
whereas that of type 1 cells was signi®cantly decreased. Consistent
with these results, in PB T cells of BP patients, the majority of both
CD4+ and CD8+ type 2 cells expressed CLA and that most of the
CD4+ type 1 cells were negative for CLA; however, no selective
expression of CLA by CD8+ type 1 cells was observed. This ®nding
may suggest that CD8+ type 1 cells do not seem to migrate into the
skin based on CLA. Indeed, however, CLA+ CD8+ T cells have
been found in autoimmune vitiligo (Ogg et al, 1998), halo nevi
phenomenon (Musette et al, 1999), and toxic epidermal necrolysis
(Leyva et al, 2000). In the process of lymphocyte extravasation into
in¯amed skin, chemokines and their receptors may also play an
important part in this multistep process (Campbell and Butcher,
2000). Thus, chemokines may be differentially produced in
different diseases and then attract different T cell populations.
One of the most striking results is a signi®cantly increased
frequency of IL-10-producing cells associated with clinical
improvement by corticosteroid therapy. IL-10 is a potent anti-
in¯ammatory cytokine that was initially shown to suppress both
type 1 cell proliferation and the production of IFN-g (Borish et al,
1998). It has become clear that IL-10 also acts to inhibit production
of type 2 cytokines in addition to its effects on type 1 cytokines. It is
therefore reasonable to assume that the decreased frequency of skin-
homing IL-13-producing cells observed after remission of BP is
attributable to increased IL-10 production. Recent evidence that
systemic corticosteroids tend to suppress Th1 and enhance Th2
immune responses (Brinkmann and Kristo®c, 1995; Ramirez et al,
1996; Franchmont et al, 2000) further supports this possibility.
Although little is known as to how corticosteroids affect the
differentiation of IL-10-producing cells, a recent study shows that
corticosteroids drive CD8+ T cells towards a phenotype with high
IL-10 and reduced IL-4, IL-5, and IL-13 production (Richards
et al, 2000). Similarly, our results suggest that corticosteroids may
control in¯ammatory responses in BP by promoting expansion of
IL-10-producing cells. A number of studies have shown bene®cial
effects of IL-10 in different models of cell-mediated autoimmunity
(Mignon-Godefroy et al, 1995; Rizzo et al, 1998; Stohlman et al,
1999; Toto et al, 1999). Thus, IL-10 could be a new therapeutic
approach for the management of BP.
In conclusion, we have demonstrated that skin-homing IL-4-
and IL-13-producing cells may contribute to the ongoing in¯am-
mation of BP, whereas IL-10-producing cells may have a protective
role in the in¯ammation of BP. These results may provide
important information for the development of new therapeutic
strategies for BP.
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